TickerFacts.

Vivos Therapeutics, Inc. (VVOS): R&D Expense

Annual figures by period end, from SEC filings.

$100.0K
Year ended 2025-12-31
-20.6%
3-year compound annual growth
$200.0K2021-12-31: $200.0K2022-12-31: $200.0K2023-12-31: $100.0K2024-12-31: $100.0K2025-12-31: $100.0K$100.0K
2021-12-31 R&D Expense (USD) 2025-12-31
Period endedR&D ExpenseChange YoYSource filing
2025-12-31$100.0K0.0%2026-04-15, From 2025-01-01
2024-12-31$100.0K0.0%2026-04-15, From 2024-01-01
2023-12-31$100.0K-50.0%2025-03-31, From 2023-01-01
2022-12-31$200.0K0.0%2024-07-30, From 2022-01-01
2021-12-31$200.0Kn/a2023-03-30, From 2021-01-01

R&D Expense at similar companies

Companies with the same SEC industry code (Surgical & Medical Instruments & Apparatus), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedR&D ExpenseChange YoY
Vivos Therapeutics, Inc. (VVOS)2025-12-31$100.0K0.0%
Nephros Inc (NEPH)2025-12-31$1.34M+47.8%
Profound Medical Corp. (PROF)2025-12-31$20.60M+21.4%
Biotricity Inc. (BTCY)2026-03-31$2.76M+28.2%
Sonoma Pharmaceuticals, Inc. (SNOA)2026-03-31$2.27M+25.2%
Allurion Technologies, Inc. (ALUR)2025-12-31$7.57M-56.4%
DarioHealth Corp. (DRIO)2025-12-31$13.79M-43.0%
Baird Medical Investment Holdings Ltd (BDMD)2025-12-31$20.13M+226.0%
Nexgel, Inc. (NXGL)2025-12-31$2.0K-97.4%

Compare VVOS, NEPH, PROF, BTCY side by side · Screen every company in Surgical & Medical Instruments & Apparatus ↗